RBC Capital analyst Brian Abrahams sees 5% downside in shares of Gilead (GILD) if President Trump was referring to the company’s Biktarvy yesterday when foreshadowing a price deal of a $137 medication into the $15-$18 range. Even if Trump was not referring to Biktarvy, Gilead could have more policy exposure to price cuts than other biotech companies, the analyst tells investors in a research note. The firm remains on the sidelines with a Sector Perform rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- Optimistic Growth Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and CDC Endorsement
- Nurix Therapeutics presents data from GS-6791
- Buy Recommendation for Gilead Sciences Amid Strategic Positioning and Legal Developments
- Gilead price target raised to $145 from $135 at JPMorgan